Compare Stocks → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:BNTCNASDAQ:HSTONASDAQ:PHIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.06$0.05$0.03▼$11.15$660K0.6724,411 shs10,136 shsBNTCBenitec Biopharma$6.90+2.7%$5.06$1.86▼$9.01$17.42M1.03216,201 shs28,676 shsHSTOHistogen$0.35$0.38$0.05▼$1.05$1.50M0.9218,192 shs29 shsPHIOPhio Pharmaceuticals$0.71+4.4%$0.80$0.50▼$6.85$3.08M1.44454,855 shs217,368 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics+1.66%-3.68%-4.75%-9.84%-99.26%BNTCBenitec Biopharma+2.68%+1.17%+39.11%+124.76%+103.45%HSTOHistogen0.00%-29.98%-12.48%-5.38%-61.64%PHIOPhio Pharmaceuticals+5.22%+11.18%-3.29%+28.34%-78.67%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1848 of 5 stars3.00.00.04.83.20.00.6BNTCBenitec Biopharma1.5967 of 5 stars3.53.00.00.02.30.80.0HSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.1471 of 5 stars3.53.00.00.00.82.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,536.36% UpsideBNTCBenitec Biopharma3.00Buy$16.00131.88% UpsideHSTOHistogenN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00466.57% UpsideCurrent Analyst RatingsLatest BNTC, BLPH, HSTO, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.002/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.002/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/ABNTCBenitec Biopharma$80K223.39N/AN/A$0.12 per share57.50HSTOHistogen$3.77M0.40N/AN/A$3.13 per share0.11PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)BNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)Latest BNTC, BLPH, HSTO, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/26/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96BNTCBenitec Biopharma0.013.623.62HSTOHistogenN/A4.054.05PHIOPhio PharmaceuticalsN/A5.705.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%BNTCBenitec Biopharma52.19%HSTOHistogenN/APHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%BNTCBenitec Biopharma4.30%HSTOHistogen3.30%PHIOPhio Pharmaceuticals0.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataHSTOHistogen74.27 million4.13 millionNot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionableBNTC, BLPH, HSTO, and PHIO HeadlinesSourceHeadlinePhio Pharmaceuticals reports progress on cancer therapy PH-762investing.com - April 24 at 11:06 AMWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?benzinga.com - April 22 at 3:21 PMIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsfinance.yahoo.com - April 22 at 3:21 PMIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsglobenewswire.com - April 22 at 1:10 PMPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)globenewswire.com - April 16 at 7:30 AMPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)globenewswire.com - April 11 at 7:30 AMNational Spotlight Features Phio’s Innovative RNAi Technology Platformfinance.yahoo.com - April 3 at 10:33 AMNational Spotlight Features Phio's Innovative RNAi Technology Platformglobenewswire.com - April 3 at 7:30 AMPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Updateglobenewswire.com - April 2 at 7:30 AMPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - March 21 at 7:52 AMPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Researchglobenewswire.com - March 13 at 2:00 PMPhio Pharmaceuticals Corp PHIOmorningstar.com - March 10 at 7:10 AMAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)markets.businessinsider.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disordersfinance.yahoo.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disordersglobenewswire.com - March 6 at 10:30 AMChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Marketopprairie.com - February 23 at 1:35 PMDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030uk.finance.yahoo.com - February 14 at 10:33 AMAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)markets.businessinsider.com - February 6 at 1:30 PMPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - January 31 at 8:14 AMPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - January 28 at 12:19 PMRecent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)knoxdaily.com - January 1 at 1:39 PMPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersmsn.com - December 19 at 9:00 PMWhy Phio Pharmaceuticals Stock Is Nosedivingmsn.com - December 7 at 5:55 PMPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceedsfinance.yahoo.com - December 7 at 12:54 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.HistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.